研究单位：[1]Guangdong Association of Clinical Trials[2]FuJian Provincial Tumor Hospital Fuzhou, Fujian, China[3]Guangdong General Hospital Guangzhou, Guangdong, China[4]Cancer Hospital Affiliated To GuangXi Medical University Nanning, Guangxi, China[5]Fourth hospital of hebei medical university Shijiazhuang, Hebei, China河北医科大学第四医院[6]The First Affiliated Hospital of HaErBin Medical University Haerbin, Heilongjiang, China[7]HeNan Provincial Tumor Hospital Zhengzhou, Henan, China[8]WuHan Tongji Hospital WuHan, Hubei, China[9]HuNan Provincial Tumor Hospital Changsha, Hunan, China[10]JiangSu Provincial Tumor Hospital Nanjing, Jiangsu, China[11]The First Affiliated Hospital of NanChang University Nanchang, Jiangxi, China[12]LiaoNing Provincial Tumor Hospital Shenyang, Liaoning, China[13]ShanDong Provincial Tumor Hospital Jinan, Shandong, China[14]Linyi cancer hospital Linyi, Shandong, China[15]Changhai Hospital of Shanghai Shanghai, Shanghai, China[16]East Hospital Affiliated To Tongji University Shanghai, Shanghai, China[17]Shanghai Chest hospital of Shanghai Jiaotong University Shanghai, Shanghai, China[18]Hangzhou First People's Hospital Hangzhou, Zhejiang, China[19]The second affiliated hospital of zhejiang university school of medicine Hangzhou, Zhejiang, China[20]ZheJiang Provincial Tumor Hospital Hangzhou, Zhejiang, China[21]The First Affiliated Hospital of AnHui Medical University Hefei, Anhui, China
研究目的：
This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer and to explore the reasonable first-line therapy for Chinese population. An open-label, multi-center study will be conducted with dynamic randomization of approximately 1:1 ratio with an estimation of 308 eligible participants.
